35 results on '"Mekies, C."'
Search Results
2. Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society
- Author
-
Donzé, C., Papeix, C., Lebrun-Frénay, C., Collongues, N., de Seze, M., Dinh, A., Even, A., Scheiber-Nogueira, C., Bensa, C., Bourre, B., Carra-Dallière, C., Ciron, J., Cohen, M., Guennoc, A.M., Louapre, C., Lebreton, F., Michel, L., Maillart, E., Audoin, B., Ayrignac, X., Bernady, P., Brochet, B., Clavelou, P., Colamarino, R., Declemy, A., de Seze, J., Derache, N., Faucheux, J.-M., Heinzlef, O., Labauge, P., Laplaud, D., Lepage, E., Leray, E., Magy, L., Mathey, G., Mekies, C., Mondain, V., Planque, E., Pelletier, J., Pittion, S., Stankhof, B., Tournaire, P., Thouvenot, E., Vukusic, S., Wiertlevski, S., Zephir, H., Alchaar, H., Androdias, G., Benazet, M., Bensmail, D., Biotti, D., Blanchard-Dauphin, A., Bonnan, M., Boutière, C., Branger, P., Bresch, S., Bru, J.-P., Camdessanché, J.-P., Castel Canal, E., Coustans, M., Casez, O., Castan, B., Creange, A., Creisson, E., De Broucker, T., Depaz, R., Douay, X., Dulau, C., Durand-Dubief, F., Fagniez, O., Faucher, M., Floch, A., Fournier, M., Fromont, A., Gallien, P., Gamé, X., Gault, D., Gayou, A., Giroux, M., Gout, O., Grimaud, J., Hautecoeur, P., Kerbrat, A., Kremer, L., Kwiatkowski, A., Labeyrie, C., Lachaud, S., Lanctin-Garcia, C., Lanotte, L., Manchon, E., Maurousset, A., Milor, A.-M., Moisset, X., Mont-Cuquet, A., Moreau, T., Ouallet, J.-C., Patry, I., Peaureaux, D., Pouget, M.-C., Pourcher Martinez, V., Radot, C., Ruet, A., Saint-Val, C., Salmon, A., Taithe, F., Tatevin, P., Vaillant, M., Stahl, J.-P., Vuoto, F., Zaenker, C., and Lebrun-Frenay, C.
- Published
- 2020
- Full Text
- View/download PDF
3. PCR14 Prioritization of Social Disability Management Using a Patient Reported Outcome Questionnaire in Patients Suffering from Multiple Sclerosis (MS)
- Author
-
Donze, C., primary, Mekies, C., additional, Mouzawak, C., additional, Paillot, G., additional, Brechenmacher, L., additional, Montagu, G., additional, Nevoret, C., additional, Duburcq, A., additional, Civet, A., additional, Pau, D., additional, Berdeaux, G., additional, and Cohen, M., additional
- Published
- 2023
- Full Text
- View/download PDF
4. PCR232 Psychometric Properties of a Patient Reported Outcome Measure (PROM) Evaluating Patient Autonomy in Multiple Sclerosis (MS)
- Author
-
Mekies, C., primary, Cohen, M., additional, Mouzawak, C., additional, Paillot, G., additional, Brechenmacher, L., additional, Montagu, G., additional, Civet, A., additional, Nevoret, C., additional, Berdeaux, G., additional, Pau, D., additional, and Donze, C., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society
- Author
-
Abadie, V., Achour, C., Ader, F., Alchaar, H., Alkhedr, A., Andreux, F., Androdias, G., Arjmand, R., Audoin, B., Audry, D., Aufauvre, D., Autreaux, C., Ayrignac, X., Bailbe, M., Benazet, M., Bensa, C., Bensmail, D., Berger, E., Bernady, P., Bertagna, Y., Biotti, D., Blanchard-Dauphin, A., Bonenfant, J., Bonnan, M., Bonnemain, B., Borgel, F., Botelho-Nevers, E., Boucly, S., Bourre, B., Boutière, C., Branger, P., Brassat, D., Bresch, S., Breuil, V., Brochet, B., Brugeilles, H., Bugnon, P., Cabre, P., Camdessanché, J.-P., Carra-Dalière, C., Casez, O., Chamouard, J.-M., Chassande, B., Chataignier, P., Chbicheb, M., Chenet, A., Ciron, J., Clavelou, P., Cohen, M., Colamarino, R., Collongues, N., Coman, I., Corail, P.-R., Courtois, S., Coustans, M., Creange, A., Creisson, E., Daluzeau, N., Davenas, C., De Seze, J., Debouverie, M., Depaz, R., Derache, N., Divio, L., Douay, X., Dulau, C., Durand-Dubief, F., Edan, G., Elias, Z., Fagniez, O., Faucher, M., Faucheux, J.-M., Fournier, M., Gagneux-Brunon, A., Gaida, P., Galli, P., Gallien, P., Gaudelus, J., Gault, D., Gayou, A., Genevray, M., Gentil, A., Gere, J., Gignoux, L., Giroux, M., Givron, P., Gout, O., Grimaud, J., Guennoc, A.-M., Hadhoum, N., Hautecoeur, P., Heinzlef, O., Jaeger, M., Jeannin, S., Kremer, L., Kwiatkowski, A., Labauge, P., Labeyrie, C., Lachaud, S., Laffont, I., Lanctin-Garcia, C., Lannoy, J., Lanotte, L., Laplaud, D., Latombe, D., Lauxerois, M., Le Page, E., Lebrun-Frenay, C., Lejeune, P., Lejoyeux, P., Lemonnier, B., Leray, E., Loche, C.-M., Louapre, C., Lubetzki, C., Maarouf, A., Mada, B., Magy, L., Maillart, E., Manchon, E., Marignier, R., Marque, P., Mathey, G., Maurousset, A., Mekies, C., Merienne, M., Michel, L., Milor, A.-M., Moisset, X., Montcuquet, A., Moreau, T., Morel, N., Moussa, M., Naudillon, J.-P., Normand, M., Olive, P., Ouallet, J.-C., Outteryck, O., Pacault, C., Papeix, C., Patry, I., Peaureaux, D., Pelletier, J., Pichon, B., Pittion, S., Planque, E., Pouget, M.-C., Pourcher, V., Radot, C., Robert, I., Rocher, F., Ruet, A., Saint-Val, C., Salle, J.-Y., Salmon, A., Sartori, E., Schaeffer, S., Stankhof, B., Taithe, F., Thouvenot, E., Tizon, C., Tourbah, A., Tourniaire, P., Vaillant, M., Vermersch, P., Vidil, S., Wahab, A., Warter, M.-H., Wiertlewski, S., Wiplosz, B., Wittwer, B., Zaenker, C., Zephir, H., Lebrun, C., and Vukusic, S.
- Published
- 2019
- Full Text
- View/download PDF
6. P018 - Développement d'un outil d'auto-évaluation de l'autonomie des patients atteints de sclérose en plaques (SEP)
- Author
-
Cohen, M., primary, Berdeaux, G., additional, Donzé, C., additional, Mouzawak, C., additional, Paillot, G., additional, Brechenmacher, L., additional, Mekies, C., additional, and Civet, A., additional
- Published
- 2023
- Full Text
- View/download PDF
7. La Fédération française de neurologie (FFN)
- Author
-
Mekies, C.
- Published
- 2015
- Full Text
- View/download PDF
8. Cognitive complaint in early Parkinsonʼs disease: A pilot study
- Author
-
Dupouy, J., Ory‐Magne, F., Mekies, C., Rousseau, V., Puel, M., Rerat, K., Pariente, J., Brefel‐Courbon, C., Andrieu, P, Angibaud, G, Aranda, A, Attané, F, Azais, C, Balague, J. P, Benazet, M, Beziaud, A.C, Boulesteix, M, Boulloche, N, Carel, C, Castan, D, Colombier, C, Cousin, F, Danielli, A, Dary Auriol, M, Dechaumont, S, Fanjaud, G, Fontayne‐Aguie, S, Lafontan, J. F, Gorce, P, Guiraud‐Chaumeil, C, Kurczewski, A, Martinez, P, Perez, F, Rouané, J. R, Rougier, M. H, Salandini, A. M, Sempe, A., Schmit, E., Stambouli, N., Tardy, J., Viala, F., and Vidry, E
- Published
- 2018
- Full Text
- View/download PDF
9. Mild Alzheimer’s disease: A «Position Paper»
- Author
-
Delrieu, J., Voisin, T., Andrieu, S., Belliard, S., Belmin, J., Blanchard, F., Ceccaldi, M., Dartigues, J. F., Defontaines, B., Lehericy, S., Mekies, C., Moreaud, O., Naccache, L., Nourhashemi, F., Ousset, P. J., Pasquier, F., Payoux, P., Puisieux, F., Robert, P., Touchon, J., Vellas, B., and Dubois, B.
- Published
- 2009
- Full Text
- View/download PDF
10. Diagnosis clinical criteria of sport related concussion: Toward an operational criteria definition in France
- Author
-
Decq, P., primary, Brauge, D., additional, Calmat, A., additional, Cassoudesalle, H., additional, Dehail, P., additional, Deroche, F., additional, Frey, A., additional, Julia, M., additional, Le Van, P., additional, Lecocq, J., additional, Mekies, C., additional, Monroche, A., additional, Pariente, J., additional, Rousseau, R., additional, Vesselle, B., additional, and Einsargueix, G., additional
- Published
- 2021
- Full Text
- View/download PDF
11. Anxiety, stress and coping behaviours in primary care migraine patients: results of the SMILE study
- Author
-
Radat, F, Mekies, C, Géraud, G, Valade, D, Vivès, E, Lucas, C, Joubert, J-M, and Lantéri-Minet, M
- Published
- 2008
12. SMILE: first observational prospective cohort study of migraine in primary care in France. Description of methods and study population
- Author
-
Géraud, G, Valade, D, Lantéri-Minet, M, Radat, F, Lucas, C, Vives, E, Joubert, J M, and Mekies, C
- Published
- 2008
13. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society
- Author
-
Lebrun, C., primary, Vukusic, S., additional, Abadie, V., additional, Achour, C., additional, Ader, F., additional, Alchaar, H., additional, Alkhedr, A., additional, Andreux, F., additional, Androdias, G., additional, Arjmand, R., additional, Audoin, B., additional, Audry, D., additional, Aufauvre, D., additional, Autreaux, C., additional, Ayrignac, X., additional, Bailbe, M., additional, Benazet, M., additional, Bensa, C., additional, Bensmail, D., additional, Berger, E., additional, Bernady, P., additional, Bertagna, Y., additional, Biotti, D., additional, Blanchard-Dauphin, A., additional, Bonenfant, J., additional, Bonnan, M., additional, Bonnemain, B., additional, Borgel, F., additional, Botelho-Nevers, E., additional, Boucly, S., additional, Bourre, B., additional, Boutière, C., additional, Branger, P., additional, Brassat, D., additional, Bresch, S., additional, Breuil, V., additional, Brochet, B., additional, Brugeilles, H., additional, Bugnon, P., additional, Cabre, P., additional, Camdessanché, J.-P., additional, Carra-Dalière, C., additional, Casez, O., additional, Chamouard, J.-M., additional, Chassande, B., additional, Chataignier, P., additional, Chbicheb, M., additional, Chenet, A., additional, Ciron, J., additional, Clavelou, P., additional, Cohen, M., additional, Colamarino, R., additional, Collongues, N., additional, Coman, I., additional, Corail, P.-R., additional, Courtois, S., additional, Coustans, M., additional, Creange, A., additional, Creisson, E., additional, Daluzeau, N., additional, Davenas, C., additional, De Seze, J., additional, Debouverie, M., additional, Depaz, R., additional, Derache, N., additional, Divio, L., additional, Douay, X., additional, Dulau, C., additional, Durand-Dubief, F., additional, Edan, G., additional, Elias, Z., additional, Fagniez, O., additional, Faucher, M., additional, Faucheux, J.-M., additional, Fournier, M., additional, Gagneux-Brunon, A., additional, Gaida, P., additional, Galli, P., additional, Gallien, P., additional, Gaudelus, J., additional, Gault, D., additional, Gayou, A., additional, Genevray, M., additional, Gentil, A., additional, Gere, J., additional, Gignoux, L., additional, Giroux, M., additional, Givron, P., additional, Gout, O., additional, Grimaud, J., additional, Guennoc, A.-M., additional, Hadhoum, N., additional, Hautecoeur, P., additional, Heinzlef, O., additional, Jaeger, M., additional, Jeannin, S., additional, Kremer, L., additional, Kwiatkowski, A., additional, Labauge, P., additional, Labeyrie, C., additional, Lachaud, S., additional, Laffont, I., additional, Lanctin-Garcia, C., additional, Lannoy, J., additional, Lanotte, L., additional, Laplaud, D., additional, Latombe, D., additional, Lauxerois, M., additional, Le Page, E., additional, Lebrun-Frenay, C., additional, Lejeune, P., additional, Lejoyeux, P., additional, Lemonnier, B., additional, Leray, E., additional, Loche, C.-M., additional, Louapre, C., additional, Lubetzki, C., additional, Maarouf, A., additional, Mada, B., additional, Magy, L., additional, Maillart, E., additional, Manchon, E., additional, Marignier, R., additional, Marque, P., additional, Mathey, G., additional, Maurousset, A., additional, Mekies, C., additional, Merienne, M., additional, Michel, L., additional, Milor, A.-M., additional, Moisset, X., additional, Montcuquet, A., additional, Moreau, T., additional, Morel, N., additional, Moussa, M., additional, Naudillon, J.-P., additional, Normand, M., additional, Olive, P., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pacault, C., additional, Papeix, C., additional, Patry, I., additional, Peaureaux, D., additional, Pelletier, J., additional, Pichon, B., additional, Pittion, S., additional, Planque, E., additional, Pouget, M.-C., additional, Pourcher, V., additional, Radot, C., additional, Robert, I., additional, Rocher, F., additional, Ruet, A., additional, Saint-Val, C., additional, Salle, J.-Y., additional, Salmon, A., additional, Sartori, E., additional, Schaeffer, S., additional, Stankhof, B., additional, Taithe, F., additional, Thouvenot, E., additional, Tizon, C., additional, Tourbah, A., additional, Tourniaire, P., additional, Vaillant, M., additional, Vermersch, P., additional, Vidil, S., additional, Wahab, A., additional, Warter, M.-H., additional, Wiertlewski, S., additional, Wiplosz, B., additional, Wittwer, B., additional, Zaenker, C., additional, and Zephir, H., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Health-related quality of life in multiple sclerosis: Effects of natalizumab
- Author
-
Rudick, R. A., Miller, D., Hass, S., Hutchinson, M, Calabresi, P. A., Confavreux, C., Galetta, S. L., Giovannoni, G., Havrdova, E., Kappos, L., Lublin, F. D., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, Ew, Stuart, W. H., Wajgt, A., Weinstock Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., Affirm, Macdonell, SENTINEL Investigators including: R., Hughes, A., Taylor, I., Lee, Y. C., Ma, H., King, J., Kilpatrick, T., Butzkueven, H., Marriott, M., Pollard, J., Spring, P., Spies, J., Barnett, M., Dehaene, I., Vanopdenbosch, L., D’Hooghe, M., Van Zandijcke, M., Derijck, O., Seeldrayers, P., Jacquy, J., Piette, T., De Cock, C., Medaer, R., Soors, P., Vanroose, E., Vanderhoven, L., Nagels, G., Dubois, B., Deville, M. C., D’Haene, R., Jacques, F., Hallé, D., Gagnon, S., Likavcan, E., Murray, T. J., Bhan, V., Mackelvey, R., Maxner, C. E., Christie, S., Giaccone, R., Guzman, D. A., Melanson, M., Esfahani, F., Gomori, A. J., Nagaria, M. H., Grand’Maison, F., Berger, L., Nasreddine, Z., Duplessis, M., Brunet, D., Jackson, A., Pari, G., O’Connor, P., Gray, T., Hohol, M., Marchetti, P., Lee, L., Murray, B., Sahlas, J., Perry, J., Devonshire, V., Hooge, J., Hashimoto, S., Oger, J., Smyth, P., Rice, G., Kremenchutzky, M., Stourac, P., Kadanka, Z., Benesova, Y., Niedermayerova, I., Meluzinova, E., Marusic, P., M, Bojar, Zarubova, K., Houzvicková, E., Piková, J., Talab, R., Faculty, Hospital Olomouc, Olomouc, B. Muchova, Urbánek, K, Kettnerova, Z., Mares, J., Otruba, P., Zapletalová, O., Hradilek, P., Ddolezil, D. Dolezil, Woznicova, I., Höfer, R., Ambler J. Fiedler, Z. Ambler J. Fiedler, Sucha, J., Matousek, V., Rektor, I., Dufek, M., Mikulik, R., Mastik, J., Tyrlikova, I., General, Teaching Hospital, Prague, E. Havrdová, Horakova, D., Kalistová, H., Týblová, M., Ehler, E., Novotná, A., Geier, P., Soelberg Sorensen, P., Ravnborg, M., Petersen, B., Blinkenberg, M., Färkkilä, M., Harno, H., Kallela, M., Häppölä, O., Elovaara, I., Kuusisto, H., Ukkonen, M., Peltola, J., Palmio, J., Pelletier, J., Feuillet, L., Suchet, L., Dalecky, A., Tammam, D., Edan, G., Le Page, E., Mérienne, M., Yaouanq, J., Clanet, M., Mekies, C., Azais Vuillemin, C., Senard, A., Lau, G., Steinmetz, G., Warter V. Wolff, J. Warter V. Wolff, Fleury, M., Tranchant, C., Stark, E., Buckpesch Heberer, U., Henn, K. H., Skoberne, T., Schimrigk, S., Hellwig, K., Brune, N., Weiller, C., Gbadamosi, J., Röther, J., Heesen, C., Buhmann, C., Karageorgiou, C., Korakaki, D., Giannoulis, D. r., Tsiara, S., Thomaides, T., Thomopoulos, I., Papageorgiou, H., Armakola, F., Komoly, S., Rózsa, C., Matolcsi, J., Szabó, G. y., Molnár, B., Lovas, G., Dioszeghy, P., Szulics, P., Magyar, Z., Incze, J., Farkas, J., Clemens, B., Kánya, J., Valicskó, Z. s., Bense, E., Nagy, Z. s., Geréby, G., Perényi, J., Simon, Z. s., Szapper, M., Gedeon, L., Csanyi, A., Rum, G., Lipóth, S., Szegedi, A., Jávor, L., Nagy, I., Adám, I., Szirmai, I., Simó, M., Ertsey, C., I, Amrein, Kamondi, A., Harcos, P., Dobos, E., Szabó, B., Balas, V., Guseo, A., Fodor, E., Jófejü, E., Eizler, K., Csiba, L., Csépány, T., Pallagi, E., Bereczki, D., Jakab, G., Juhász, M., Bszabó, B. Szabó I. Mayer, Katona, G., Hutchinson, M., O’Dwyer, J., O’Rourke, K., Sanders, E. A. C. M., Rijk van Andel, J. F., Bomhof, M. A. M., van Erven, P., Hintzen I. Hoppenbrouwers, R. Q. Hintzen I. Hoppenbrouwers, Neuteboom, R. F., Zemel, D., van Doorn, P. A., Jacobs, B. C., Munster, E. T. h. L. Van, ter Bruggen, J. P., Bernsen, R., Jongen, P. J. H., de Smet, E. A. A., Tacken, H. F. H., Polman, C., Zwemmer, J., Nielsen, J., Kalkers, N., Kragt, J., Jasperse, B., Willoughby, E., Anderson, N. E., Barber, A., Anderson, T., Parkin, P. J., Fink, J., Avery, S., Mason, D., Kwiecinski, H., Zakrzewska Pniewska, B., Kaminska, A., Podlecka, A., Nojszewska, M., Czlonkowska, A., Zaborski, J., Wicha, W., Kruszewska Ozimowska, J., Darda Ledzion, L., Selmaj, K., Mochecka Thoelke, A., Pentela Nowicka, J., Walczak, A., Stasiolek, M., Stelmasiak, Z., Bartosik Psujek, H., Mitosek Szewczyk, K., Belniak, E., Chyrchel, U., Maciejowski, M., Strzyzewska Lubos, L., Lubos, L., Matusik, E., Maciejek, Z., Niezgodzinska Maciejek, A., Sobczynska, D., Slotala, T., Wawrzyniak, S., Kochanowicz K. Kuczynski, J. Kochanowicz K. Kuczynski, Zimnoch, R., Pryszmont, M., Drozdowski, W., Baniukiewicz, E., Kulakowska, A., Borowik, H., Lewonowska, M., Szczudlik, A., Róg, T., Gryz Kurek, E., Pankiewicz, J., Furgal, J., Kimkowicz, A., Fryze, W., Wierbicki, T., Michalak, L., Kowalewska, J., Swiatkiewicz, J., Hillert, J., Åkesson, E, Fredrikson, S., Diener, P, Olsson, T., Wallström, E., Fpiehl, F. Piehl L. Hopia, Brundin, L., Marta, M., Andersson, M., Lycke, J., Runmarker, B., Malmeström, C., Vaghfeldt, P., Skoog, B., Schluep, M., Bogousslavskyr, J., Du Pasquier, R., Achtnichts, L., Kuhle, J., Buitrago Telez, C., Schläger, R., Naegelin, Y., Eraksoy, M., Bebek, N., Akman Demir, G., Topcuoglu, B., Kurtuncu, M., Istanbul, University, Istanbul:, A. Siva, Saip, S., Altintas, A., Kiyat, A., Sharief, M., Kasti, M., Lim, E. T., Rashid, W., Silber, E., Saldanha, G., Hawkins, C., Mamutse, G., Woolmore, J., Hawkes, C., Findley, L., Dasilva, R., Gunasekara, H., Palace, J., Cader, Z., Littleton, E., Burke, G., Sharrack O. Suliman, B. Sharrack O. Suliman, Klaffke, S., Swash, M., Dhillon, H., Bates, D., Westwood, M., Nichol, P., Barnes, D., Wren, D., Stoy, N., Robertson, N., Pickersgill, T., Pearson, O., Lawthom, C., Young, C., Mills, R., Lecky, B., Ford, C., Katzman, J., Rosenberg, G., Cooper, J., Wrubel, B., Richardson, B., Lynch, S., Ridings, L., Mcvey, A., Nowack, W., Rae Grant, A., Mackin, G. A., Castaldo, J. E., Spikol, L. J., Carter, J., Wingerchuk, D., Caselli, R., Dodick, D., Scarberry, S., Bailly, R., Garnaas, K., Haake, B., Rossman, H., Belkin, M., Boudouris, W. D., Pierce, R. P., Mass, M., Yadav, V., Bourdette, D., Whitham, R. H., Heitzman, D., Martin, A., Greenfield, C. F., Agius, M., Richman, D. P., Vijayan, N., Wheelock, V. L., Reder, A., Arnason, B., Noronha, A., Balabanov, R., Ray, A., Sheremata, W., Delgado, S., Shebert, B., Maldonado, J., Bowen, J., Garden, G. A., Distad, B. J., Carrithers, M., Rizzo, M., Vollmer, T., Reiningerova, J., Guarnaccia, J., Lo, A., Richardson, G. B., Fazekas, F., Enzinger, C., Seifert, T., Storch, M., Strasser Fuchs, S., Berger, T., Dilitz, E., Egg, R., Deisenhammer, F., Decoo, : D, Lampaert, J., Bartholome, E., Bier, J., Stenager, : E., Rasmussen, M., Binzer, M., Shorsh, K., Christensen, M., Soelberg Sørensen, P., Hansen, H. J., Bech, E., Petersen, T., Kirkegaard, M., Eralinna, : J., Ruutiainen, J., Soilu Hänninen, M., Säkö, E., Laaksonen, M., Reunanen, M., Remes, A., Keskinarkaus, I., Moreau, : T., Noblet, M., Rouaud, O., Couvreur, G., Lepage, E., Drapier, S., De Burghgraeve, V., Merienne, M., Cahagne, V., Gout, O., Deschamps, R., Le Canuet, P., Moulignier, A., Vermersch, P., De Seze, J., Stojkovic, T., Griffié, G., Engles, Ferriby, D., Debouverie, M., Pittion Vouyouvitch, S., Lacour, J. C., Lubetzki, C., Youssov, K., Mrejen, S., Charles, P., Yaici, S., Clavelou, P., Aufauvre, D., Renouil Guy, N., Cesaro, P., Degos, F., Benisty, S., Rumbach, L., Decavel, P., Blanc, S., Aubertin, P., Riche, G., Brochet, B., Ouallet, J. C., Anne, O., Menck, : S., Grupe, A., Gutmann, E., Lensch, E., Fucik, E., Heitmann, S., Hartung, H. P., Schröter, M., Kurz, F. M. W., Heidenreich, F., Trebst, C., Pul, R., Hohlfeld, R., Krumbholz, M., Pellkofer, H., Haas, J., Segert, A., Meyer, R., Anagnostou, P., Kabus, C., Poehlau, D., Schneider, K., Hoffmann, V., Zettl, U., Steinhagen, V., Adler, S., Steinbrecher E. Rothenfusser Körber, A. Steinbrecher E. Rothenfusser Körber, Zellner, R., Baum, K., Günther, A., Bläsing, H., Stoll, G., Gold, R., Bayas, A., Kleinschnitz, C., Limmroth, V., Katsarava, Z., Kastrup, O., Haller, P., Stoeve, S., Höbel, D., Oschmann, P., Voigt, K., Burger, C. V., Abramsky, : O., Karusiss, D., Achiron, A., Kishner, I., Stern, Y., Sarove Pinhas, I., Dolev, M., Magalashvili, D., Pozzili, : C., Lenzi, D., Scontrini, A., Millefiorini, E., Buttinelli, C., Gallo, P., Ranzato, F., Tiberio, M., Perini, P., Laroni, Alice, Marrosu, M., Cocco P. Marchi, E. Cocco P. Marchi, Spinicci, G., Massole, S., Mascia, M., Floris, G., Trojano, M., Bellacosa, A., Paolicelli, D., Bosco Zimatore, G., Simone, I. L., Giorelli, M., Di Monte, E., Mancardi, GIOVANNI LUIGI, Pizzorno, M., Murialdo, A., Narciso, E., Capello, A., Comi, G., Martinelli, V., Rodegher, M., Esposito, F., Colombo, B., Rossi, P., Polman, : C. H., Jasperse, M. M. S., Zwemmer, J. N. P., Kragt, J. J., De Smet, E., Tacken, H., Frequin, S. T. F. M., Siegers, H. P., Mauser, H. W., Fernandez Fernandez, : O., León, A., Romero, F., Alonso, A., Tamayo, J., Montalban, X., Nos, C., Pelayo, R., Tellez, N., Rio, J., Tintore, M., Arbizu, T., Romero, L., Moral, E., Martinez, S., Kappos, : L., Wilmes, S., Karabudak, : R., Kurne, A., Erdem, S., Siva, A., Atamer, A., Bilgili, F., Topcular, B., Giovannoni, : G., Lava, : N., Murnane, M., Dentinger, M., Zimmerman, E., Reiss, M., Gupta, V., Scott, T., Brillman, J., Kunschner, L., Wright, D., Perel, A., Babu, A., Rivera, V., Killian, J., Hutton, G., Lai, E., Picone, M., Cadivid, D., Kamin, S., Shanawani, M., Gauthier, S., Morgan, A., Buckle, G., Margolin, D., Kwen, P. L., Garg, N., Munschauer, F., Khatri, B., Rassouli, M., Saxena, V., Ahmed, A., Turner, A., Fox, E., Couch, C., Tyler, R., Horvit, A., Fodor, P., Humphries, S., Wynn, D., Nagar, C., O’Brien, D., Allen, N., Turel, A., Friedenberg, S., Carlson, J., Hosey, J., Crayton, H., Richert, J., Tornatore, C., Sirdofsky, M., Greenstein, J., Shpigel, Y., Mandel, S., Adbelhak, T., Schmerler, M., Zadikoff, C., Rorick, M., Reed, R., Elias, S., Feit, H., Angus, E., Sripathi, N., Herbert, J., Kiprovski, K., Qu, X., Del Bene, M., Mattson, D., Hingtgen, C., Fleck, J., Horak, H., Javerbaum, J., Elmore, R., Garcia, E., Tasch, E., Gruener, G., Celesia, G., Chawla, J., Miller, A., Drexler, E., Keilson, M., Wolintz, R., Drasby, E., Muscat, P., Belden, J., Sullivan, R., Cohen, J., Stone, L., Marrie, R. A., Fox, R., Hughes, B., Babikian, P., Jacoby, M., Doro, J., Puricelli, M., Boudoris, W., Pierce, R., Eggenberger, E., Birbeck, G., Martin, J., Kaufman, D., Stuart, W., English, J. B., Stuart, D. S., Gilbert, R. W., Kaufman, M., Putman, S., Diedrich, A., Follmer, R., Pelletier, D., Waubant, E., Cree, B., Genain, C., Goodin, D., Patwa, H., Rizo, M., Kitaj, M., Blevins, J., Smith, T., Mcgee, F., Honeycutt, W., Brown, M., Isa, A., Nieves Quinones, D., Krupp, L., Smiroldo, J., Zarif, M., Perkins, C., Sumner, A., Fisher, A., Gutierrez, A., Jacoby, R., Svoboda, S., Dorn, D., Groeschel, A., Steingo, B., Kishner, R., Cohen, B., Melen, O., Simuni, T., Zee, P., Cohan, S., Yerby, M., Hendin, B., Levine, T., Tamm, H., Travis, L. H., Freedman, S. M., Tim, R., Ferrell, W., Stefoski, D., Stevens, S., Katsamakis, G., Topel, J., Ko, M., Gelber, D., Fortin, C., Green, B., Logan, W., Carpenter, D., Temple, L., Sadiq, S., Sylvester, A., Sim, G., Mihai, C., Vertino, M., Jubelt, B., Mejico, L., Riskind, P., Cabo, A., Paskavitz, J., Moonis, M., Bashir J. Brockington, K. Bashir J. Brockington, Nicholas, A., Slaughter, R., Archer S. Harik, R. Archer S. Harik, Haddad, N., Pippenger, M. A., Van den Noort, S., Thai, G., Olek, M., Demetriou, M., Shin, R., Calabresi, P., Rus, H., Bever, C., Johnson, K., Sherbert, R., Herndon, R., Uschmann, H., Chandler, A., Markowitz, C., Jacobs, D., Balcer, L., Mitchell, G., Chakravorty, S., Heyman, R., Stauber, Z., Goodman, A., Segal, B., Schwid, S., Samkoff, L., Levin, M., Jacewicz, M., Menkes, D., Pulsinelli, W., Frohman, E., Racke, M., Hawker, K., Ulrich, R., Panitch, H., Hamill, R., Tandon, R., Dulaney, E., Simnad, V., Miller, J., Wooten, G. F., Harrison, M., Doherty, M., Wundes, A., Distad, J., Kachuck, N., Berkovich, R., Burnett, M., Sahai, S., Bandari, D., Weiner, L., Storey, J. R., Beesley, B., Hart, D., Moses, H., Sriram, S., Fang, J., O’Duffy, A., Kita, M., Taylor, L., Elliott, M., Roberts, J., Jeffery, D., Maxwell, S., Lefkowitz, D., Kumar, S., Sinclair, M., Radue, E. W., de Vera, A., Bacelar, O., and Kuster, P.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Visual analogue scale ,Health Status ,Population ,Pain ,Comorbidity ,Placebo ,Antibodies ,law.invention ,Natalizumab ,Randomized controlled trial ,Quality of life ,Double-Blind Method ,law ,Internal medicine ,Surveys and Questionnaires ,Monoclonal ,medicine ,Prevalence ,Humans ,Longitudinal Studies ,education ,Humanized ,education.field_of_study ,Expanded Disability Status Scale ,Neuroscience (all) ,business.industry ,Antibodies, Monoclonal ,Antibodies, Monoclonal, Humanized ,Female ,Patient Satisfaction ,Treatment Outcome ,United States ,Quality of Life ,Multiple sclerosis ,medicine.disease ,Neurology ,Physical therapy ,Neurology (clinical) ,business ,medicine.drug - Abstract
Objective To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab. Methods HRQoL data were available from 2,113 multiple sclerosis patients in natalizumab clinical studies. In the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) study, patients received natalizumab 300mg (n = 627) or placebo (n = 315); in the Safety and Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis (SENTINEL) study, patients received interferon beta-1a (IFN-β-1a) plus natalizumab 300mg (n = 589), or IFN-β-1a plus placebo (n = 582). The Short Form-36 (SF-36) and a subject global assessment visual analog scale were administered at baseline and weeks 24, 52, and 104. Prespecified analyses included changes from baseline to week 104 in SF-36 and visual analog scale scores. Odds ratios for clinically meaningful improvement or worsening on the SF-36 Physical Component Summary (PCS) and Mental Component Summary were calculated. Results Mean baseline SF-36 scores were significantly less than the general US population and correlated with Expanded Disability Status Scale scores, sustained disability progression, relapse number, and increased volume of brain magnetic resonance imaging lesions. Natalizumab significantly improved SF-36 PCS and Mental Component Summary scores at week 104 in AFFIRM. PCS changes were significantly improved by week 24 and at all subsequent time points. Natalizumab-treated patients in both studies were more likely to experience clinically important improvement and less likely to experience clinically important deterioration on the SF-36 PCS. The visual analog scale also showed significantly improved HRQoL with natalizumab. Interpretation HRQoL was impaired in relapsing multiple sclerosis patients, correlated with severity of disease as measured by neurological ratings or magnetic resonance imaging, and improved significantly with natalizumab. Ann Neurol 2007
- Published
- 2007
15. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study
- Author
-
Clanet, M., Kappos, L., Hartung, H.P., Hohlfeld, R., Kristoferitsch, W., Schrieber, A., Schlederer, A., Seeldrayers, P., Piette, A., Papacostas, S., Kyriallis, K., Pantzaris, A., Brochet, B., Gayou, A., Rouanet, M., Rouant, F., Confavreux, C., Riche, G., Blanc, S., Achiti, J., Magnier, C., Aubertin, P., Mekies, C., Brassat, D., Thalamas, C., Vuilleman, C., Senard, A., Lau, G., Cesaro, P., Degos, F., Defer, G., Schaeffer, S., Edan, G., de Marco, A., Cahagne, V., Belliard, S., Lyon-Caen, O., Stankoff, B., Lubetzki, C., Arnulf, I., Damier, P., Pelletier, J., Tamman, D., Suchet, L., Dalecky, A., Rumbach, L., Moulin, A., Berger, E., Roullet, E., Pez, D., Heinzlef, O., Lecanuet, P., Vermersch, P., Engles, A., Dengler, R., Heidenreich, F., Lindert, A., Koehler, A., Windhagen, A., Steiner, A., Zschenderlein, R., Luenemann, J., Gelderblom, H., Kassim, N., Storch-Hagenlocher, B., Koerner, A., Vogt-Schaden, A., Stingle, A., Storch-Hagenlocher, A., Sailer, 27449, Matzke, A., Dose, A., Weiler, C., Kunze, K., Heesen, C., Bamborschke, P., Petereit, H., Liu, A., Nolden, A., Grunwald, F., Menck, A., Grupe, A., Rieckmann, P., Weilbach, A., Flachenecker, A., Chan, A., Maurer, A., de Keyser, Jacques, Zwanniken, G., Zorgdrager, A., Montalban, X., Nos, A., Fernandez, O., Tamayo, J.A., Romero, F., Arbizu, T., Martinez-Yelamos, A., Martin, A, and Casado, A.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Injections, Intramuscular ,Central nervous system disease ,03 medical and health sciences ,Disability Evaluation ,0302 clinical medicine ,Multiple Sclerosis, Relapsing-Remitting ,Adjuvants, Immunologic ,Internal medicine ,Epidemiology ,Clinical endpoint ,medicine ,Humans ,030212 general & internal medicine ,Clinical efficacy ,business.industry ,Incidence (epidemiology) ,Multiple sclerosis ,Interferon beta-1a ,Interferon-beta ,medicine.disease ,Surgery ,Europe ,Interferon β 1a ,Treatment Outcome ,Neurology ,Disease Progression ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,medicine.drug ,Follow-Up Studies - Abstract
Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNb-1a in patients with relapsing MS from the European IFNb-1a Dose-C omparison Study. Methods: Patients who completed 36 months of treatment (Part 1) of the European IFNb-1a Dose-C omparison Study were given the option to continue double-blind treatment with IFNb-1a 30 mcg or 60 mcg IM once weekly (Part 2). Analyses of 48-month data were performed on sustained disability progression, relapses, and neutralizing antibody (NA b) formation. Results: O f 608/802 subjects who completed 36 months of treatment, 493 subjects continued treatment and 446 completed 48 months of treatment and follow-up. IFNb-1a 30 mcg and 60 mcg IM once weekly were equally effective for up to 48 months. There were no significant differences between doses over 48 months on any of the clinical endpoints, including rate of disability progression, cumulative percentage of patients who progressed (48% and 43%, respectively), and annual relapse rates; relapses tended to decrease over 48 months. The incidence of patients who were positive for NAbs at any time during the study was low in both treatment groups. Conclusion: C ompared with 60-mcg IM IFNb-1a once weekly, a dose of 30 mcg IM IFNb-1a once weekly maintains the same clinical efficacy over four years.
- Published
- 2004
16. Problème du maintien du traitement à long terme
- Author
-
Mekies, C. and Borgel, F.
- Published
- 2010
- Full Text
- View/download PDF
17. État des lieux des activités d’éducation thérapeutique dans la SEP à l’échelon national
- Author
-
Mekies, C., primary, Cohen, M., additional, and Lebrun-Fresnay, C., additional
- Published
- 2014
- Full Text
- View/download PDF
18. Neurologie et sport
- Author
-
Mekies, C., primary
- Published
- 2014
- Full Text
- View/download PDF
19. Enquête de satisfaction sur le programme de formation à l’auto-injection d’AVONEX® PEN™, Facil’AVO
- Author
-
Coustans, M., primary, Borgel, F., additional, Mekies, C., additional, Servan, J., additional, Nouet, S., additional, and Moreau, T., additional
- Published
- 2014
- Full Text
- View/download PDF
20. De l’acceptabilité à l’adhésion au traitement de fond. À l’orée des formes orales ?
- Author
-
Mekies, C., primary
- Published
- 2014
- Full Text
- View/download PDF
21. L’estime de soi : un indicateur d’évaluation d’un programme d’éducation thérapeutique du patient ?
- Author
-
Laroche, C., primary, Amy, C., additional, Dejean, G., additional, Mekies, C., additional, and Clanet, M., additional
- Published
- 2014
- Full Text
- View/download PDF
22. Enquête nationale de pratique sur l’éducation thérapeutique dans la SEP et le Parkinson en France
- Author
-
Tourette-Turgis, C., primary, Rebillon, M., additional, and Mekies, C., additional
- Published
- 2013
- Full Text
- View/download PDF
23. Clinical determinants of migraine preventive treatment: Contribution of SMILE, an observational survey of primary care migraine management in France
- Author
-
Valade, D, primary, Lantéri-Minet, M, additional, Radat, F, additional, Mekies, C, additional, Lucas, C, additional, Vivès, E, additional, Joubert, JM, additional, and Géraud, G, additional
- Published
- 2010
- Full Text
- View/download PDF
24. Smile: First Observational Prospective Cohort Study of Migraine in Primary Care in France. Description of Methods and Study Population
- Author
-
Géraud, G, primary, Valade, D, additional, Lantéri-Minet, M, additional, Radat, F, additional, Lucas, C, additional, Vives, E, additional, Joubert, JM, additional, and Mekies, C, additional
- Published
- 2007
- Full Text
- View/download PDF
25. [New imaging methods by nuclear magnetic resonance in multiple sclerosis]
- Author
-
Mekies C, Isabelle BERRY, Manelfe C, and Clanet M
- Subjects
Magnetic Resonance Spectroscopy ,Multiple Sclerosis ,Brain ,Humans ,Magnetic Resonance Imaging - Abstract
Magnetic resonance imaging (MRI) has rapidly attained a major position among the examinations used in the diagnostic approach of multiple sclerosis because it is highly sensitive in demonstrating lesions. However, these lesional images may have several meanings, and there is the problem of distinguishing between oedema, which is said to reflect recent lesions, and gliosis which is thought to betray old lesions. The intrinsic MRI parameters studied (i.e. relaxation times) are unable to make this distinction, whereas it is provided by paramagnetic contrast media such as gadolinium. There is no correlation between the changes observed at MRI and the severity of the disease. Another problem is the accuracy of lesion localization, since visualization is predominantly macroscopic. This raises several questions about the demonstration of correlations between clinical signs and site of the lesion(s). At the moment, several teams of neuroradiologists are trying to find the most reliable method to determine the size of the lesion. The possible prognostic value of this size and its changes as time goes by are other parameters to be considered once the basic diagnosis has been made.
- Published
- 1991
26. Mild Alzheimer's disease: a <<position paper>>.
- Author
-
Delrieu J, Voisin T, Andrieu S, Belliard S, Belmin J, Blanchard F, Ceccaldi M, Dartigues JF, Defontaines B, Lehericy S, Mekies C, Moreaud O, Naccache L, Nourhashemi F, Ousset PJ, Pasquier F, Payoux P, Puisieux F, Robert P, and Touchon J
- Published
- 2009
- Full Text
- View/download PDF
27. Early diagnosis and treatment of transient ischemic events in adults - May 2004,Prise en charge diagnostique et traitement immédiat de l'accident ischémique transitoire de l'adulte: Mai 2004
- Author
-
Chevallier, A., Albucher, J. -F, Cazaubon, M., Elalamy, I., Mas, J. -L, Meder, J. -F, Mollard, J. -M, Rusterholtz, T., Varenne, O., Verny, M., Martel, P., Allaert, F. -A, Almeras, M., Becker, F., Billault, C., Conri, C., Derumeaux, G., Dupont, P., Filloux, Y., Gudin Vallerin, M., Harston, S., Le Mauff, P., Mounier-Vehier, F., Catherine Oppenheim, Piquet, P., Touboul, P. -J, Attali, C., Baietto, M., Bensoussan, J. -L, Bonafé, A., Borgat, C., Bouchet, C., Boulliat, J., Bousquet, A., Bousser, M. -G, Bressollette, L., Buchon, D., Busseuil, C., Chatel, M., Cosson-Stanescu, R., Coudray, N., Laigue Arfi, V., Wazières, B., Decamps, A., Denolle, T., Devoize, J. -L, Dormont, D., Dujardin, J. -J, Gavid, B., Genty, A., Giroud, M., Gras, P., Guilmot, J. -L, Hache, J. -C, Jonquille, C., Julia, P., Jullien, G., Koskas, F., Kownator, S., Le Goaziou, M. -F, Le Hello, C., Le Heuzey, J. -Y, Lebrin, P., Lecompte, T., Legout, A., Leys, D., Luizy, F., Mathonnet, F., Mekies, C., Michon-Pasturel, U., Moulin, T., Mourad, J. -J, Ortolan, B., Ourabah, R., Pasco-Papon, A., Paturel, J. -L, Pertuiset, B., Philippe, J. -M, Plassart, F., Plat, M., Pruvo, J. -P, Schved, J. -F, Sommereisen, J. -P, Stephan, D., Suciu, S., Vergnenegre, A., Voisin, T., Wahl, D., and Woimant, F.
28. Diagnostic management and immediate treatment of transient ischemic attack in adults - May 2004,Prise en charge diagnostique et traitement immédiat de l'accident ischémique transitoire de l'adulte - Mai 2004
- Author
-
Albucher, J. -F, Cazaubon, M., Elalamy, I., Mas, J. -L, Meder, J. -F, Mollard, J. -M, Rusterholtz, T., Varenne, O., Verny, M., Martel, P., Allaert, F. -A, Almeras, M., Becker, F., Billault, C., Conri, C., Derumeaux, G., Dupont, P., Filloux, Y., Vallerin, M. G., Harston, S., Le Mauff, P., Mounier-Vehier, F., Catherine Oppenheim, Piquet, P., Touboul, P. -J, Attali, C., Baietto, M., Bensoussan, J. -L, Bonafe, A., Borgat, C., Bouchet, C., Boulliat, J., Bousquet, A., Bousser, M. -G, Bressollette, L., Buchon, D., Busseuil, C., Chatel, M., Cosson-Stanescu, R., Coudray, N., Laigue Arfi, V., Wazieres, B., Decamps, A., Denolle, T., Devoize, J. -L, Dormont, D., Dujardin, J. -J, Gavid, B., Genty, A., Giroud, M., Gras, P., Guilmot, J. -L, Hache, J. -C, Jonquille, C., Julia, P., Jullien, G., Koskas, F., Kownator, S., Le Goaziou, M. -F, Le Hello, C., Le Heuzey, J. -Y, Lebrin, P., Lecompte, T., Legout, A., Leys, D., Luizy, F., Mathonnet, F., Mekies, C., Michon-Pasturel, U., Moulin, T., Mourad, J. -J, Ortolan, B., Ourabah, R., Pasco-Papon, A., Paturel, J. -L, Pertuiset, B., Philippe, J. -M, Plassart, F., Plat, M., Pruvo, J. -P, Schved, J. -F, Sommereisen, J. -P, Stephan, D., Suciu, S., Vergnenegre, A., Voisin, T., Wahl, D., and Woimant, F.
29. Enquête de satisfaction sur le programme de formation à l’auto-injection d’AVONEX®PEN™, Facil’AVO
- Author
-
Coustans, M., Borgel, F., Mekies, C., Servan, J., Nouet, S., and Moreau, T.
- Published
- 2014
- Full Text
- View/download PDF
30. Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS).
- Author
-
Donzé C, Mekies C, Paillot G, Vermersch P, Montagu G, Brechenmacher L, Civet A, Pau D, Mouzawak C, and Cohen M
- Abstract
Background: In multiple sclerosis (MS), the measure of the loss of autonomy appears to be particularly relevant to provide adapted and personalized responses to improve the quality of care in routine clinical practice. In this context, this research aimed to develop a new patient-reported outcome measure (PROM) evaluating MS patients' autonomy, in order to provide an easy-to-use tool in the context of the relations between healthcare professionals and patients with MS, and to be used in future clinical trials for treatment assessment., Methods: This research was conducted in two consecutive stages. First, a preliminary questionnaire was generated using an innovative sociological approach for MS (after literature review, patient interviews, experts' opinion, and patient focus groups). This questionnaire was then completed by patients with MS, before the reduction of the scale while maintaining relevant information, using a principal component analysis. The internal consistency reliability was assessed using the Cronbach's alpha coefficient. The external validity was evaluated using an analysis of variance to estimate the relation between the reduced questionnaire dimension scores and disease severity classes assessed by the SymptoMScreen questionnaire., Results: The first qualitative step of the research led to provide a definition of disease-related autonomy as perceived by patients (to be able to carry out the roles the patient thinks the most important whether or not he/she receives assistance) as well as an associated taxonomy. On this basis, a preliminary questionnaire of 131 items grouped into 13 social dimensions was generated (seven dimensions with 63 questions concerning all the patients, and six dimensions with 68 questions concerning specific patients). This questionnaire was completed on a web platform by 653 analyzable patients with MS. Their main characteristics were as follows: female patients: 83.6 %, mean age at MS diagnosis: 34.8 ± 10.5 years, age ≥40 years at data collection: 68.1 %, MS duration ≥5 years: 68.4 %, severe MS (SymptoMScreen score ≥30): 36.8 %. On the basis on completed 131-item questionnaires, it was reduced in a 36-item short form of 10 social dimensions (five dimensions with 19 questions concerning all the patients, and five dimensions with 17 questions concerning specific patients). The internal consistency of the final questionnaire was good for all the dimensions, as the Cronbach's alpha coefficient ranged from 0.77 to 0.85 depending on dimensions. The construct validity of the questionnaire was also confirmed., Conclusion: Our research allowed to build the first PROM designed to evaluate the autonomy of patients suffering from MS: the Multiple Sclerosis Autonomy Scale (MSAS). A confirmatory study, conducted in patients with MS using this validated questionnaire, is currently conducted., Competing Interests: Declaration of competing interest The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Cécile Donzé: consulting and speaking honoraria from Biogen, BMS, Coloplast, Merck, Novartis, Roche, Sanofi, and Teva; Claude Mekies: honoraria for scientific advisory boards participation or contribution to scientific meetings from Bayer, Biogen, BMS, Celgène, Eisai, Genzyme, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, and Téva; Géraud Paillot: no conflict of interest; Patrick Vermersch: honoraria, contribution to meetings from AB Science, Biogen, BMS-Celgene, Imcyse, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva, and research supports from Merck, Novartis, and Sanofi-Genzyme; Guillaume Montagu: as an employee of unknowns SAS, consulting for Alexion, Astellas, BMS, Celltrion, Chiesi, Gilead, Novo Nordisk, Pfizer, and Roche; Lucie Brechenmacher, Alexandre Civet and David Pau are employees from Roche SAS, France; Catherine Mouzawak: honoraria for consulting, scientific advisory boards participation, or other activities from Biogen, Janssen, Merck, Novartis, Sanofi, and Roche; Mikael Cohen: consulting honoraria from Ad Scientiam, Alexion, Biogen, BMS, Horizon Therapeutics, Merck, Novartis, and Roche., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
31. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.
- Author
-
De Sèze J, Suchet L, Mekies C, Manchon E, Labauge P, Guennoc AM, Defer G, Clavelou P, Castelnovo G, Bourre B, Bensa-Koscher C, Al Khedr A, Le Mao J, Villemur L, Bouée S, Luciani L, and Vermersch P
- Abstract
The treatment strategy in relapsing multiple sclerosis (RMS) is a complex decision requiring individualization of treatment sequences to maximize clinical outcomes. Current local and international guidelines do not provide specific recommendation on the use of immune reconstitution therapy (IRT) as alternative to continuous immunosuppression in the management of RMS. The objective of the program was to provide consensus-based expert opinion on the optimal use of IRT in the management of RMS. A Delphi method was performed from May 2022 to July 2022. Nineteen clinical assertions were developed by a scientific committee and sent to 14 French clinical experts in MS alongside published literature. Two consecutive reproducible anonymous votes were conducted. Consensus on recommendations was achieved when more than 75% of the respondents agreed or disagreed with the clinical assertions. After the second round, consensus was achieved amongst 16 out of 19 propositions: 13 clinical assertions had a 100% consensus, 3 clinical assertions a consensus above 75% and 3 without consensus. Expert-agreed consensus is provided on topics related to the benefit of the early use of IRT from immunological and clinical perspectives, profiles of patients who may benefit most from the IRT strategy (e.g. patients with family planning, patient preference and lifestyle requirements). These French expert consensuses provide up-to-date relevant guidance on the use of IRT in clinical practice. The current program reflects status of knowledge in 2022 and should be updated in timely manner when further clinical data in IRT become available., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
32. Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.
- Author
-
Tourbah A, Papeix C, Tourniaire P, Rerat K, Meite M, Durand B, Lamy F, Chouette I, and Mekies C
- Subjects
- Fingolimod Hydrochloride adverse effects, France, Humans, Immunosuppressive Agents adverse effects, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting drug therapy
- Abstract
Background: Timely treatment switching is an important strategy in optimising management of patients with relapsing remitting multiple sclerosis (RRMS). Patient preferences, as well as clinical benefit, may contribute to the switch decision. Information on reasons determining switching choices and on outcome according to the reason for switching is scarce. Study objectives were to describe the consequences of switching to fingolimod in terms of clinical improvement according to the reasons underlying the switch and to evaluate treatment acceptability from the patient's perspective., Methods: This prospective observational study was conducted by 71 neurologists in France and included patients with RRMS switching to fingolimod following ≥6 months treatment with a first-line disease modifying treatment (DMT). Reasons for switching were documented. Patients were evaluated at inclusion and 12 months after initiating fingolimod. Physicians documented clinical status by relapse activity, disability (EDSS) at each visit and improvement with the Clinical Global Impression - Change (CGI-C) at Month 12. Patients rated improvement at Month 12 with the Patient Global Impression - Change (PGI-C) and treatment acceptability with the ACCEPT® questionnaire. Adverse events reported during fingolimod treatment were documented., Results: Overall 232 patients were recruited of whom 190 could be analysed. Multiple reasons for switching were frequently given; 113 patients (59.4%) switched from a first-line injectable DMT. Switching was motivated by disease worsening in 161 patients (84.7%), tolerability in 35 (18.4%) and patient preference in 58 (30.5%). During the follow-up period, 38 patients (20.0%) experienced at least one exacerbation. The mean EDSS score was stable (2.0 ± 1.3 at inclusion; 2.0 ± 1.5 at M12). With the CGI-C, 67 patients (38.7%) were considered improved and 23 (13.3%) worsened. Although no obvious differences in CGI-C ratings were observed as a function of the reason for switching, when patient preferences entered into the decision, the proportion of patients considered minimally improved was somewhat higher (37.7%) and the proportion considered unchanged somewhat lower (41.5%). With the PGI-C, more patients rated themselves improved than were rated as improved by the physician: of 64 patients rated as 'no change' on the CGI-C, 21 (32.8%) rated themselves as 'improved' and 10 (15.6%) as 'worsened'. The overall level of agreement between the two measures was moderate (κ = 0.48 [95% CI: 0.35 - 0.60]). The mean general treatment acceptability score on the ACCEPT® questionnaire was 42.7 [95%CI: 34.5 - 50.9] at inclusion (reflecting acceptability of the previous DMT) and 64.6 [95%CI: 57.6 - 71.6] at M12 (reflecting acceptability of fingolimod). Mean dimension scores ranged from 36.7 for effectiveness to 72.2 for medication inconvenience at inclusion and from 63.4 for effectiveness to 96.8 for medication inconvenience at M12. The frequency and nature of reported adverse events was consistent with the well-characterised safety profile of fingolimod., Conclusion: Most patients switching from a first DMT to fingolimod do so due to persistent disease activity during the initial treatment, although patient preferences are also important. Switching is followed by a reduction in disease activity, perceived improvement in the clinical state of the patient and improved acceptability of treatment., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2020
- Full Text
- View/download PDF
33. Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis.
- Author
-
Vermersch P, De Sèze J, Clavelou P, Durand-Dubief F, Maillart E, Mekies C, Moreau T, Papeix C, Tourbah A, and Labauge P
- Subjects
- France, Humans, Magnetic Resonance Imaging, Disease Management, Immunologic Factors therapeutic use, Multiple Sclerosis diagnostic imaging, Multiple Sclerosis drug therapy, Practice Guidelines as Topic, Practice Patterns, Physicians', Treatment Failure
- Abstract
Objectives: In the management of multiple sclerosis (MS), defining criteria for identification of suboptimal therapy responses and switching treatment is essential to avoid worsening. Despite the lack of a standardised definition, criteria for first-line treatment are well documented in the literature, based on clinical measures or magnetic resonance imaging (MRI) (gadolinium enhancing [Gd
+ ] lesions or new/enlarging T2 lesions) assessed during the first 6-18 months after treatment initiation. However, it is unknown whether the same criteria can be used for second-line treatment failure., Methods: Five regional boards involving 36 French MS experts were convened to discuss published literature regarding criteria for first- and second-line treatment failure, and to identify differences in local therapeutic practices. A national board of 11 experts was subsequently conducted to identify convergences and differences between regions, and to propose second-line criteria for the definition of therapeutic failure., Results: Published information is lacking regarding second-line treatment failure criteria. In light of this, regional differences in current therapeutic practices are justifiable. Due to the risk-benefit ratio of these treatments and limited options for third-line treatments, the authors recommend a different therapeutic approach when assessing second-line treatment failure. The treatment switch for second-line treatment should be informed by confirmed disease progression, after 6 months, or combined clinical and MRI outcomes, but only after at least 1 year of treatment., Conclusions: Experts compared therapeutic attitudes and practices regarding second-line treatment failure between French regions. They identified convergences that were used to propose a national agreement on second-line treatment failure criteria, which should be evaluated in real-life prospective cohorts., (Copyright © 2019. Published by Elsevier B.V.)- Published
- 2019
- Full Text
- View/download PDF
34. Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?
- Author
-
Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, and Pittion S
- Subjects
- Anti-Bacterial Agents therapeutic use, Humans, Multicenter Studies as Topic, Multiple Sclerosis therapy, Bacteriuria therapy, Immunosuppressive Agents therapeutic use, Multiple Sclerosis complications
- Published
- 2017
- Full Text
- View/download PDF
35. Country breakout session highlights.
- Author
-
Ghezzi A, Filli L, Solaro C, Mekies C, Landete L, and Lycke J
- Subjects
- Cannabidiol therapeutic use, Dronabinol therapeutic use, Drug Combinations, Europe, Gait Disorders, Neurologic etiology, Gait Disorders, Neurologic therapy, Humans, Multiple Sclerosis complications, Muscle Spasticity etiology, Muscle Spasticity therapy, Multiple Sclerosis therapy
- Abstract
At the 2016 MS Experts Summit, country-relevant aspects pertaining to the management of symptoms and disability in multiple sclerosis (MS), with emphasis on those associated with spasticity, were explored in interactive country breakout sessions chaired by selected MS experts. Attendees had the opportunity to review and discuss topics in their own native language. After feedback from each session leader, key messages were collated and presented in a Plenary Session by Summit chair, Professor Angelo Ghezzi. Topics at this year's Summit included: gait tracking (Germany/Switzerland); the Care Alliance against MS spasticity (Italy); MS spasticity and associated symptoms (France); improvement in MS symptoms and functionality and patients' independence (Spain); Swedish MS guidelines (Sweden/Rest of World).
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.